Participant enrollment underway in phase II trial of concizumab in hemophilia A and B patients Aug. 21, 2017 No Comments
Portola Pharmaceuticals is assigned a PDUFA date for the factor Xa inhibitor antidote andexanet Aug. 16, 2017 No Comments
Zelboraf granted priority review and breakthrough therapy designation for Erdheim-Chester disease Aug. 8, 2017 No Comments
BioMarin to open additional phase III studies based on phase I/II data of BMN-270 Aug. 3, 2017 No Comments
MHCSZ-123 antibody offers strong antithrombotic effects by inhibition of collagen binding July 31, 2017 No Comments
FDA grants fast track designation to caplacizumab for acquired thrombotic thrombocytopenic purpura July 26, 2017 No Comments
RSS